Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Italy Brings In New Measures In 2026 To Tackle Overtourism - 2As tetanus vaccination rates decline, doctors worry about rising case numbers
- 3The most effective method to Connect Successfully with Teachers in a Web based Setting
- 4The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- 5Vote in favor of your Number one kind of juice
- This Week In Space podcast: Episode 192 — Space, 2026!
- ‘Serving is not just a place’: Bayside Church Granite Bay reimagines annual mission amid conflict in Mexico
- Surge of off‑lease electric vehicles expected to drive down used EV prices
- RFK Jr.'s vaccine panel delays hepatitis B shot vote after chaotic meeting
- Iran, Hezbollah fire rockets at Israel during Passover celebrations
- Met Gala 2026 will celebrate fashion as an 'embodied art form': A guide to the theme, dress code, cochairs and hosting committee of the starry event
- Vote In favor of Your Favored Kind Of Organic product
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- AstraZeneca to invest $2 billion as part of US manufacturing push
